DexCom, Inc. (NASDAQ:DXCM) Holdings Trimmed by Principal Financial Group Inc.

Principal Financial Group Inc. lessened its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 13.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 584,952 shares of the medical device company's stock after selling 94,215 shares during the period. Principal Financial Group Inc. owned 0.15% of DexCom worth $45,492,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Versant Capital Management Inc acquired a new stake in DexCom during the 4th quarter worth approximately $25,000. Heck Capital Advisors LLC bought a new position in shares of DexCom during the fourth quarter valued at $38,000. RPg Family Wealth Advisory LLC bought a new position in shares of DexCom during the third quarter valued at $57,000. Covestor Ltd raised its stake in shares of DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company's stock valued at $64,000 after acquiring an additional 335 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its stake in shares of DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock valued at $65,000 after acquiring an additional 265 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Insider Activity

In related news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,083 shares of company stock valued at $3,309,794 in the last 90 days. 0.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on DXCM shares. Citigroup raised their target price on DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Royal Bank of Canada cut their price objective on DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Oppenheimer cut their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Canaccord Genuity Group boosted their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Finally, Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $99.06.

DexCom Stock Down 0.6 %

Shares of NASDAQ:DXCM traded down $0.56 during midday trading on Friday, reaching $88.78. The company's stock had a trading volume of 3,729,437 shares, compared to its average volume of 3,632,823. The firm has a market capitalization of $34.69 billion, a P/E ratio of 62.08, a PEG ratio of 2.31 and a beta of 1.14. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The firm has a 50 day moving average of $83.26 and a 200-day moving average of $75.94.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.